DK3536797T5 - Forhøjet transgenudtrykkelse og -forarbejdning - Google Patents

Forhøjet transgenudtrykkelse og -forarbejdning Download PDF

Info

Publication number
DK3536797T5
DK3536797T5 DK19153376.9T DK19153376T DK3536797T5 DK 3536797 T5 DK3536797 T5 DK 3536797T5 DK 19153376 T DK19153376 T DK 19153376T DK 3536797 T5 DK3536797 T5 DK 3536797T5
Authority
DK
Denmark
Prior art keywords
processing
transgene expression
elevated
elevated transgene
expression
Prior art date
Application number
DK19153376.9T
Other languages
Danish (da)
English (en)
Other versions
DK3536797T3 (da
Inventor
Fourn Valérie Le
Nicolas Mermod
Alexandre Regamey
Montse Buceta
Déborah Ley
Niamh Harraghy
Kaja Kostyrko
Pierre-Alain Giro
David Calabrese
Original Assignee
Selexis Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Selexis Sa filed Critical Selexis Sa
Application granted granted Critical
Publication of DK3536797T3 publication Critical patent/DK3536797T3/da
Publication of DK3536797T5 publication Critical patent/DK3536797T5/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241Tumor Necrosis Factors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/10Plasmid DNA
    • C12N2800/106Plasmid DNA for vertebrates
    • C12N2800/107Plasmid DNA for vertebrates for mammalian
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/90Vectors containing a transposable element
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/46Vector systems having a special element relevant for transcription elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK19153376.9T 2013-02-01 2014-02-01 Forhøjet transgenudtrykkelse og -forarbejdning DK3536797T5 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361759802P 2013-02-01 2013-02-01
US201361800244P 2013-03-15 2013-03-15
US201361806634P 2013-03-29 2013-03-29
EP14708935.3A EP2951309B1 (en) 2013-02-01 2014-02-01 Enhanced transgene expression and processing

Publications (2)

Publication Number Publication Date
DK3536797T3 DK3536797T3 (da) 2023-04-03
DK3536797T5 true DK3536797T5 (da) 2024-09-02

Family

ID=50239688

Family Applications (2)

Application Number Title Priority Date Filing Date
DK19153376.9T DK3536797T5 (da) 2013-02-01 2014-02-01 Forhøjet transgenudtrykkelse og -forarbejdning
DK14708935.3T DK2951309T3 (en) 2013-02-01 2014-02-01 INCREASED TRANSGEN EXPRESSION AND PROCESSING

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK14708935.3T DK2951309T3 (en) 2013-02-01 2014-02-01 INCREASED TRANSGEN EXPRESSION AND PROCESSING

Country Status (20)

Country Link
US (1) US11898154B2 (https=)
EP (2) EP3536797B1 (https=)
JP (1) JP6563816B2 (https=)
KR (1) KR102235603B1 (https=)
CN (2) CN105073995A (https=)
AU (2) AU2014210856B2 (https=)
CA (1) CA2898878C (https=)
DK (2) DK3536797T5 (https=)
ES (2) ES2717175T3 (https=)
FI (1) FI3536797T3 (https=)
HU (2) HUE061494T2 (https=)
IL (1) IL240198B (https=)
LT (1) LT2951309T (https=)
PL (2) PL3536797T3 (https=)
PT (2) PT2951309T (https=)
RU (1) RU2711505C9 (https=)
SG (2) SG11201505487UA (https=)
SI (1) SI2951309T1 (https=)
WO (1) WO2014118619A2 (https=)
ZA (1) ZA201506419B (https=)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109576265B (zh) * 2014-04-01 2020-08-28 三生国健药业(上海)股份有限公司 一种含mar核心片段的动物细胞表达载体
CN105154473B (zh) * 2015-09-30 2019-03-01 上海细胞治疗研究院 一种高效安全的转座子整合系统及其用途
WO2017061354A1 (ja) * 2015-10-06 2017-04-13 国立大学法人 岡山大学 遺伝子発現用カセット及びその産生物
JP2017070224A (ja) * 2015-10-06 2017-04-13 国立大学法人 岡山大学 遺伝子発現用カセット及びその産生物
JP6871679B2 (ja) * 2016-03-23 2021-05-12 国立大学法人 岡山大学 遺伝子発現用カセット及びその産生物
CN108473982A (zh) 2015-12-24 2018-08-31 思兰克斯有限公司 用于蛋白生产的改进的真核细胞及其制备方法
ITUA20161610A1 (it) * 2016-03-14 2017-09-14 Angela Anna Messina Composto peptidico farmacologicamente attivo, procedimento per la sua preparazione e suo uso.
EP3219803A1 (en) * 2016-03-15 2017-09-20 Max-Delbrück-Centrum für Molekulare Medizin Enhanced sleeping beauty transposons, kits and methods of transposition
EP3219800A1 (en) * 2016-03-15 2017-09-20 Max-Delbrück-Centrum Für Molekulare Medizin A transposon-based transfection system for primary cells
MX2018013499A (es) * 2016-05-03 2019-09-11 Lonza Ag Modulacion del metabolismo lipidico para la produccion de proteinas.
WO2018066492A1 (ja) * 2016-10-03 2018-04-12 第一三共株式会社 Hspa5遺伝子のプロモーター
AU2017378482B2 (en) 2016-12-16 2024-06-13 R&D Systems, Inc. Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods
US11278570B2 (en) 2016-12-16 2022-03-22 B-Mogen Biotechnologies, Inc. Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods
WO2018224162A1 (en) * 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for characterizing loss of antigen presentation
KR102712841B1 (ko) * 2017-09-29 2024-10-04 (주)벳바젠 심부전의 예방 또는 치료용 약학적 조성물
CN109929839B (zh) * 2017-12-18 2021-02-12 华东师范大学 拆分型单碱基基因编辑系统及其应用
CN108504692B (zh) * 2018-03-26 2021-07-23 安徽大学 一种基因敲除cho细胞株的构建方法及其在治疗性重组蛋白表达中的应用
EP3794128A1 (en) * 2018-05-18 2021-03-24 Sorbonne Universite Molecular tools and methods for transgene integration and their transposition dependent expression
AU2019288669B2 (en) 2018-06-21 2025-06-26 R&D Systems, Inc. Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods
RU2686102C1 (ru) * 2018-08-07 2019-04-24 Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) Рекомбинантный вектор для создания плазмидных генетических конструкций, обладающих повышенной длительностью экспрессии целевых генов
WO2020049106A1 (en) * 2018-09-05 2020-03-12 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft A method for engineering synthetic cis-regulatory dna
WO2020081537A1 (en) * 2018-10-16 2020-04-23 Texas Tech University System Method to express, purify, and biotinylate eukaryotic cell-derived major histocompatibility complexes
US20230193341A1 (en) 2018-10-24 2023-06-22 Selexis Sa Expression systems, recombinant cells and uses thereof
PT3894549T (pt) 2018-12-10 2024-10-16 Amgen Inc Transposase piggybac mutada
EP3902910A1 (en) * 2018-12-24 2021-11-03 Selexis S.A. Characterization and inactivation of endogenous retroviruses in chinese hamster ovary cells
WO2020152532A1 (en) 2019-01-23 2020-07-30 Enzyvant Therapeutics Gmbh Method of ameliorating a pro-inflammatory immunophenotype in farber disease subjects by repeated administration of a recombinant human acid ceramidase
IT201900002321A1 (it) * 2019-02-18 2020-08-18 Univ Degli Studi Padova Peptidi con attivita' antitumorale
WO2020198556A2 (en) * 2019-03-27 2020-10-01 Phoenix Tissue Repair, Inc. Systems and methods for producing collagen 7 compositions
CN110006866B (zh) * 2019-04-16 2022-04-22 杭州迈尔德生物科技有限公司 一种阿片类活性物质的通用检测方法及其检测试剂盒
WO2020228721A1 (en) * 2019-05-13 2020-11-19 Lin Mei Chun Method and kit for monitoring cancer
CA3154452A1 (en) * 2019-10-10 2021-04-15 The Regents Of The University Of California Methods to stabilize mammalian cells
IL270306A (en) 2019-10-30 2021-05-31 Yeda Res & Dev Prevention and treatment of pre-myeloid and myeloid malignancies
CN112813099A (zh) * 2019-11-15 2021-05-18 上海细胞治疗集团有限公司 一种在活化的t细胞中具有高活性的启动子
CN110863008B (zh) * 2019-11-22 2020-10-16 昆明学院 Mar序列调控弱启动子构建高效表达载体的方法
CA3164931A1 (en) 2019-12-24 2021-07-01 Selexis Sa Targeted integration in mammalian sequences enhancing gene expression
JP7483907B2 (ja) * 2020-02-19 2024-05-15 ウーシー バイオロジクス アイルランド リミテッド 強化された発現系及びその使用方法
CN111500629B (zh) * 2020-04-17 2021-11-19 安徽中盛溯源生物科技有限公司 一种高表达层粘连蛋白-511变体的方法及其应用
EP4149966A4 (en) * 2020-05-14 2024-08-07 Seattle Children's Hospital (DBA Seattle Children's Research Institute) DOUBLE PROMOTOR SYSTEMS
US12173304B2 (en) * 2020-07-08 2024-12-24 Neuracle Genetics Inc. Intron fragments
CN113881703B (zh) * 2021-10-11 2022-06-21 中国人民解放军军事科学院军事医学研究院 一种提高cho细胞同源重组效率的方法及其相关产品和应用
CN116440269B (zh) * 2022-01-10 2024-02-09 华中农业大学 Slc35a1基因作为靶点在防治猪流行性腹泻病中的应用
CN114958914B (zh) * 2022-06-06 2023-09-26 新乡医学院 一种人类及哺乳动物细胞附着体表达载体、构建方法和应用
CN115896227A (zh) * 2022-12-20 2023-04-04 西北农林科技大学 一种鉴定外源基因整合位点以增强转基因表达的方法
GB202305637D0 (en) 2023-04-17 2023-05-31 Macomics Ltd Transposons, vectors and genetically engineered cells

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731178A (en) 1990-03-21 1998-03-24 Behringwerke Aktiengesellschaft Attachment-elements for stimulation of eukaryotic expression systems
JP3656277B2 (ja) * 1995-05-17 2005-06-08 味の素株式会社 組換えdna法によるトランスグルタミナーゼの効率的製造法
DK1395669T3 (da) 2001-01-26 2009-11-16 Selexis Sa Matriks bindingsregioner og fremgangsmåder til anvendelse af disse
US20040235011A1 (en) 2002-06-26 2004-11-25 Cooper Richard K. Production of multimeric proteins
WO2004065581A2 (en) * 2003-01-15 2004-08-05 Discovery Genomics, Inc. Transposon-insulator element delivery systems
US7244616B2 (en) * 2003-06-27 2007-07-17 Bayer Pharmaceuticals Corporation Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells
WO2005040377A2 (en) 2003-10-24 2005-05-06 Selexis S.A. High efficiency gene transfer and expression in mammalian cells by a multiple transfection procedure of matrix attachment region sequences
ES2292271B1 (es) * 2004-05-20 2009-02-16 Proyecto De Biomedicina Cima, S.L. Un vector hibrido adenovirus-alfavirus para la administracion eficaz y expresion de genes terapeuticos en celulas tumorales.
MX2007015540A (es) * 2005-06-10 2008-03-07 Genentech Inc Mejora de la expresion de anticuerpos utilizando vectores que contienen elementos aislantes.
DK2205618T3 (en) 2007-09-26 2017-02-20 Intrexon Corp SYNTHETIC 5 'NON-TRANSLATED REGIONS, EXPRESSION VECTORS AND PROCEDURES FOR INCREASING TRANSGENIC EXPRESSION
US20090247609A1 (en) 2007-12-20 2009-10-01 Hitto Kaufmann Sm-protein based secretion engineering
WO2010008564A2 (en) * 2008-07-16 2010-01-21 Recombinetics Plaice dna transposon system
EP2417263B1 (en) * 2009-04-09 2015-09-23 ProteoVec Holding L.L.C. Production of proteins using transposon-based vectors
KR20120099376A (ko) 2009-09-18 2012-09-10 셀렉시스 에스. 에이. 강화된 전이 유전자 발현과 공정 방법 및 그 산물

Also Published As

Publication number Publication date
DK2951309T3 (en) 2019-04-23
RU2711505C2 (ru) 2020-01-17
AU2019250224B2 (en) 2022-05-12
CN120718957A (zh) 2025-09-30
SG10201803758XA (en) 2018-06-28
SG11201505487UA (en) 2015-08-28
CA2898878A1 (en) 2014-08-07
WO2014118619A2 (en) 2014-08-07
JP2016504922A (ja) 2016-02-18
LT2951309T (lt) 2019-03-25
JP6563816B2 (ja) 2019-08-21
KR20150123803A (ko) 2015-11-04
US20150361451A1 (en) 2015-12-17
ES2717175T3 (es) 2019-06-19
EP2951309B1 (en) 2019-01-30
AU2014210856B2 (en) 2019-10-24
ES2940433T3 (es) 2023-05-08
KR102235603B1 (ko) 2021-04-05
WO2014118619A3 (en) 2014-10-30
AU2019250224A1 (en) 2019-11-07
HK1216323A1 (en) 2016-11-04
HUE043103T2 (hu) 2019-08-28
IL240198B (en) 2019-10-31
IL240198A0 (en) 2015-09-24
CA2898878C (en) 2020-04-28
RU2711505C9 (ru) 2020-08-12
PL3536797T3 (pl) 2023-09-11
AU2014210856A1 (en) 2015-07-30
RU2015127667A (ru) 2017-03-06
FI3536797T3 (fi) 2023-03-23
PT3536797T (pt) 2023-03-15
EP3536797B1 (en) 2023-01-04
ZA201506419B (en) 2017-02-22
CN105073995A (zh) 2015-11-18
US11898154B2 (en) 2024-02-13
HUE061494T2 (hu) 2023-07-28
PL2951309T3 (pl) 2019-06-28
PT2951309T (pt) 2019-04-03
SI2951309T1 (sl) 2019-04-30
EP3536797A1 (en) 2019-09-11
EP2951309A2 (en) 2015-12-09
DK3536797T3 (da) 2023-04-03

Similar Documents

Publication Publication Date Title
DK3536797T5 (da) Forhøjet transgenudtrykkelse og -forarbejdning
BR112015019373A2 (pt) processamento e transformação de biomassa
DK3043784T3 (da) Arylethere og anvendelser deraf
DK3003039T3 (da) Methyl/fluor-pyridinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser og fluor-pyrimidinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser
DK3063144T3 (da) Antiparasitære og pesticid-isoxazolinforbindelser
DK2962100T3 (da) Tuberkulosebiomarkører og anvendelser deraf
EP3020508A4 (en) Machining device
HRP20182173T8 (hr) Duhanski materijal i njegova obrada
IL244370A0 (en) Short-term hashes
DK2969005T3 (da) Attenuerede influenzavira og -vacciner
BR112015024661A2 (pt) silo e silo elevado
EP3034888A4 (en) FAN
FI10308U1 (fi) Kalankäsittelylaite
BR302013006566S1 (pt) Configuração aplicada em manopla
BR302013004931S1 (pt) Configuração aplicada em manopla
UA28558S (uk) Розгортка опакування
UA28560S (uk) Розгортка опакування
UA28555S (uk) Розгортка опакування
UA28556S (uk) Розгортка опакування
UA28636S (uk) Розгортка опакування
UA28557S (uk) Розгортка опакування
UA28564S (uk) Розгортка опакування
UA28553S (uk) Розгортка опакування
UA28559S (uk) Розгортка опакування
UA28550S (uk) Розгортка опакування